The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel.
Noa Ben-Baruch
Consultant or Advisory Role - Teva
Tamar Peretz-Yablonski
No relevant relationships to disclose
Georgeta Fried
No relevant relationships to disclose
Moshe J. Inbar
No relevant relationships to disclose
Yousef Samih
No relevant relationships to disclose
Victoria Neiman
No relevant relationships to disclose
Bella Nisenbaum
No relevant relationships to disclose
Karen Drumea
No relevant relationships to disclose
Neil Friedman
No relevant relationships to disclose
Rony Weitzen
No relevant relationships to disclose
Tamar Safra
No relevant relationships to disclose
Lior Soussan-Gutman
Employment or Leadership Position - Teva
Addie Dvir
Employment or Leadership Position - Teva
Phil Stephens
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Kai Wang
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Jeffrey S. Ross
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine